Procrastinator's Marathon 2024 Virtual Program for Pharmacists and Pharmacy Technicians

Description

This is your last chance to obtain live continuing educational credits for pharmacy license renewal. This knowledge-based continuing education program (offered via Webex) will update the participant regarding Hyperlipidemia, OUD, DVT, Update on New Drugs, and Off Label Use of Migraine Medicine. Don't miss this very relevant information!

Agenda

7:15 AM	Registration/Connect
8:00 AM	Lipid On A Prayer: Current Recommendations for Treating Patients with Hyperlipidemia- Garrett Allegra, PharmD
9:00 AM	The New Era of Opioid Use Disorder- Olivia Caron, PharmD, BCACP, CPP
10:00 AM	Break
10:15 AM	Breaking Down DVT: Tailoring Treatment for Special Populations- Caroline McKenna, PharmD
11:15 AM	Update on New Drugs 2024- Avery Weekman, PharmD
12:15 PM	Break
12:30 PM	When Off Label Makes Good Migraine Medicine- Brian Loftus, MD
1:30 PM	Adjourn

Co-sponsored by:

Target Audience

Pharmacists and Pharmacy Technicians in all aspects of Pharmacy

Objectives

• Describe the epidemiology, pathophysiology, and complications of hyperlipidemia (P/PT)
• Recognize available treatments for hyperlipidemia and their associated class, mechanism of action, and dosing recommendations (P/PT)
• Construct a treatment regimen for a given patient case based on AHA/ACC guideline recommendations (P)
• Summarize and compare medications for opioid use disorder (P/PT)
• Examine common myths related to the use of buprenorphine and highlight novel induction strategies (P/PT)
• Apply non-stigmatizing harm reduction concepts to patient cases (P)
• Develop treatment plans for VTE in the context of patient-specific comorbidities (P)
• Discuss the importance of monitoring for patient safety, including appropriate lab testing, and s/sx of clotting and bleeding (P)
• List 8 medications that were newly approved by the FDA in 2024 (P/PT)
• Review the mechanism of action of these medications and their role in their respective disease states (P/PT)
• Describe the dosing, precautions, common side effects, and key patient counseling points for these medications (P)
• Discuss the myth of triptan overuse headache (P)
• Review Topiramate over 100 mg (P)
• Review Zonisamide, Duloxetine/Desvenlafaxine, and Candesartan for migraine prevention (P)

Faculty

• Garrett Allegra, PharmD
• Olivia A. Caron, PharmD, BCACP, CPP
• Brian Loftus, MD
• Caroline McKenna, PharmD
• Avery Weekman, PharmD